Study of AZD4956 for advanced solid tumors with DNA repair problems
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic cancer that has spread to other parts of your body.
- You are generally well enough to do light activities (like walking or light housework) without help.
- Your life expectancy is at least about 3 months.
- Your organs (like liver, kidneys, and bone marrow) are working well enough.
- If you are a woman, you must not be pregnant or breastfeeding, and you must not donate eggs for about 6 months after the study ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called Saruparib in people with advanced solid tumors that haven't responded to standard treatments. The study will see how the drug is absorbed, distributed, and eliminated from the body.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
This early-phase study tests ART6043 in people with advanced or metastatic solid tumors, and in some parts with breast cancer plus specific gene changes. The goal is to see how well it works and whether it is safe, sometimes combined with olaparib.
Hear when a new Solid Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.